Clorox (CLX)
NYSEConsumer StaplesHousehold & Personal ProductsSnapshot 2026-10-29
$88.67+2.11%
Close 2026-10-29 · 1-day change
NYSEConsumer StaplesHousehold & Personal ProductsSnapshot 2026-10-29
Research Workspace
Put CLX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Household Products is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue is contracting — down about 4% over the past year.
View GrowthManagement screens strong on capital allocation.
View ManagementExpectations look high — the market is pricing in about 33% growth a year, above the roughly 9% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskClorox’s case rests on restoring organic growth through pricing strength and strategic initiatives. Recent revenue remains weak, with Q4 FY2026 down 2% year over year despite an earnings beat. The beat supports earnings, but it has not yet reversed the sales decline. CLX trades at 16× P/E versus a 16.2× peer median; the market prices more growth than we forecast. The new CEO faces a stated management commitment running behind. Our model puts the next-quarter miss near 20%, and the Mania market cycle adds valuation risk. Peer multiples imply a price about 33% below where it trades. The thesis is on watch, and this read is provisional.
Trailing returns as of 2026-10-29. CLX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 18 analysts currently covering CLX (as of Oct 2026).
Based on 6 Wall Street analysts offering 12-month price targets for CLX in the last 4 months.
Continue this research
Compare CLX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CLX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Household Products — fair value, gap to price, and forward P/E.
Compare the value case
Put CLX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Reuters reports a CEO appointment; leadership transition may affect execution, but no strategic or financial impact is specified.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $88.67
The last 12 months of price, then the range of analyst 12-month targets from today’s $88.67.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
CEO appointment is relevant to execution, but the item provides no details on strategic or financial implications.
Indicates ongoing recovery issues impacting sales.
Dividend increase suggests confidence in profitability.
Caution on recovery indicates ongoing sales challenges.
Deteriorating fundamentals indicate sales issues.
Strategic initiatives may enhance growth prospects.
Advances: Address sales decline and return to organic growth
Focus on growth plan supports addressing sales decline.
